Replies to post #442793 on NorthWest Biotherapeutics Inc (NWBO)

[Reefrad]

Breast cancer is not even remotely as rare as GBM, we are talking orders of magnitude here. 1 in 8 women will be diagnosed with breast cancer in their lifetime, hence the FDA regulated mammography screening. GBM is a super rare disease which is not even screened for.

[MI Dendream]

GBM is currently about a $3B market. Nearly every patient in that figure will have DCVax added to their regimen. That leads to a substantial growth in the MARKET for GBM.

Do your own math, but I estimate DCVax-L for GBM quickly plateaus at a run rate of about $4-5B. After that price increases will account for its growth in that indication. DCVax is already being used in other indications within the United Kingdom.

[Maverick0408]

Not true. There are at least 10 to 20 times more breast cancer cases than GBM. Here’s some statistics:

https://www.breastcancer.org/symptoms/understand_bc/statistics

[dennisdave]

mistyped I mean market revenue